1268P JASPER: Efficacy and safety of first-line (1L) niraparib plus a programmed death receptor 1 inhibitor (PD-1i) in patients with advanced non-small cell lung cancer (NSCLC) von Ramalingam, S.S., Thara, E., Rao, S., Awad, M.M., Dowlati, A., Haque, B., Veatch, A.L., Stinchcombe, T., Dy, G.K., Spigel, D.R., Singh, N. Iyer, Evilevitch, L., Wang, Z., Tang, Y., Teslenko, I., Roychoudhury, M.

Volltext

JAVELIN Lung 100: updated design of a phase 3 trial of avelumab vs platinum doublet chemotherapy as first-line (1L) treatment for metastatic or recurrent PD-L1+ non-small-cell lung... von Reck, M., Yang, C.-H., Postmus, P.E., Barlesi, F., Font, E.F., Thomas, M., Kim, T.M., Cobo Dols, M., Skuladottir, H., Park, K., Sullivan, R., Veatch, A.L., Pavlakis, N., Dreosti, L.M., Özgüroğlu, M., Morgillo, F., Schlichting, M., Teofilovici, F., Chand, V., Westeel, V.

Volltext